This review discusses the global clinical burden and consequences of MASLD as a multisystem disease, briefly describing the natural history, pathophysiology, risk stratification and case finding of the disease, and focuses on the new and promising metabolism-based pharmacotherapies targeting the liver and cardiovascular-kidney-metabolic comorbidities of MASLD. Current areas of uncertainty where further research is needed are also discussed.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Targher, Giovanni
Writing – Original Draft Preparation
;
2025-01-01
Abstract
This review discusses the global clinical burden and consequences of MASLD as a multisystem disease, briefly describing the natural history, pathophysiology, risk stratification and case finding of the disease, and focuses on the new and promising metabolism-based pharmacotherapies targeting the liver and cardiovascular-kidney-metabolic comorbidities of MASLD. Current areas of uncertainty where further research is needed are also discussed.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
